Chapter 15: Antimicrobial Drugs

Foundations of Antimicrobial Modern Medicine

  • Antimicrobial drugs are therapeutic agents used to fight infections caused by various microorganisms, including bacteria, viruses, fungi, and parasites.

  • They serve as the cornerstone of modern medicine.

  • According to the U.S. Centers for Disease Control and Prevention (CDC):

    • Antimicrobials are among the most commonly prescribed drugs in the United States.

    • More than 200200 million prescriptions for antibiotics are written each year.

    • Annually in the United States, there are approximately 2.82.8 million infections caused by antibiotic-resistant bacteria.

    • About 35,00035,000 people die per year as a result of these resistant infections.

Terminology and Classification of Antimicrobial Drugs

  • Antimicrobial: Derived from Greek words anti (against), mikros (little), and bios (life). Refers to all agents that act against microbial organisms.

  • Antibiotic: Derived from Greek words anti (against) and biotikos (concerning life).

    • By strict definition, antibiotics refer to substances produced by microorganisms that act against another microorganism.

    • This definition excludes synthetic substances (e.g., sulfonamides and quinolones) and semisynthetic substances (e.g., methicillin and amoxicillin).

  • Target-Based Categorization:

    • Antibacterial drugs: Treat bacterial infections.

    • Antiviral drugs: Target viral infections.

    • Antifungal drugs: Target fungal infections.

    • Antiparasitic drugs: Treat protozoan and helminthic (worm) infections.

Historical Development of Antimicrobials

  • Before antimicrobial drugs, routine infections were often fatal:

    • Strep throat could cause death.

    • Infections were the primary cause of war-related deaths throughout most of history.

  • Tonics and potions claiming to cure infections existed for hundreds of years, but the first safe and effective drugs only appeared in the 20th century.

  • Alexander Fleming (1928):

    • Studied Staphylococcus aureus.

    • Observed a culture plate contaminated with mold where S. aureus was unable to grow near the mold.

    • He determined the mold excreted a compound that inhibited bacteria, which he named penicillin after the Penicillium species of mold.

  • Mass Production:

    • Penicillin was mass-produced by 1940 due to the onset of World War II.

    • It was primarily used to combat streptococcal and staphylococcal infections that caused high death tolls among soldiers.

  • Streptomycin:

    • Isolated from a culture of the soil bacterium Streptomyces griseus.

    • Found to be effective against tuberculosis.

Spectrum of Activity and Effects on Bacteria

  • Spectrum: The selective effect of antimicrobial drugs regarding which microbes they affect.

    • Broad-spectrum drugs: Effective against both Gram-negative and Gram-positive bacteria.

    • Examples: Levofloxacin and Ciprofloxacin.

    • Narrow-spectrum drugs: Effective against a limited range of bacteria.

    • Examples: Bacitracin and Vancomycin.

  • Preservation of Microbiota:

    • Narrow-spectrum drugs are generally preferred because they cause less disruption to the normal microbiota.

    • Using these requires a firm identification of the causative pathogen.

  • Bacteriostatic vs. Bactericidal:

    • Bacteriostatic: Prevents bacteria from growing.

    • Typically targets bacterial protein synthesis and metabolic pathways.

    • Bactericidal: Kills bacteria.

    • Typically targets bacterial cell walls, cell membranes, or nucleic acids.

  • Variable Effectiveness: A drug's status as bactericidal or bacteriostatic can change based on:

    • Pathogen type.

    • Dose.

    • Length of the drug regimen.

    • Pathogen load.

    • Route of administration.

  • Drawbacks of Bactericidal Drugs:

    • Elimination of normal microbiota.

    • Potential for a spike in bacterial toxin release (e.g., LPS from Gram-negatives), which can be deadly.

Natural, Synthetic, and Semisynthetic Drugs

  • Antibiotics: Naturally occurring antimicrobial compounds.

  • Synthetic antimicrobials: Manufactured by chemical processes.

  • Semisynthetic antimicrobials: Chemical modifications of naturally occurring antibiotics.

    • Modification involves adding chemical groups (e.g., R groups) to enhance desirable properties.

    • Example: Ampicillin and amoxicillin are derived by modifying Penicillin G. These modifications result in a broader spectrum (affecting Gram-negative bacteria) compared to the original Penicillin G, which only targets Gram-positive bacteria.

  • Drug Generations:

    • First-generation drugs: Result from a first round of chemical modification.

    • Second-generation drugs: Result from a second round of chemical modification.

    • Successive generations often feature extended spectrums, increased stability, and the ability to circumvent resistance mechanisms.

Factors Impacting Drug Development and Safety

  • Selective Toxicity: Antimicrobial drugs must kill the pathogen without harming the host.

  • Therapeutic Index: The ratio of the maximum tolerated (safe) dose to the minimum effective (therapeutic) dose.

    • Therapeutic Index=Maximum safe doseMinimum effective dose\text{Therapeutic Index} = \frac{\text{Maximum safe dose}}{\text{Minimum effective dose}}

    • A high therapeutic index is safer because the drug is effective well below the toxic threshold.

    • A narrow therapeutic index requires closer monitoring for toxicity.

Routes of Administration and Pharmacokinetics

  • Oral Administration:

    • Preferred due to ease of use.

    • Drug must be stable in gastric acid and absorbed in the intestines.

  • Parenteral Administration (Injection or Infusion):

    • Intravenous (IV): Into a vein.

    • Intramuscular (IM): Into muscle tissue.

    • Subcutaneous: Under the skin.

    • Downsides: Requires needles/IV lines, basic medical training, and may involve injection discomfort or phobia.

  • Half-Life (t1/2t_{1/2}):

    • The time it takes for half of a dose to be eliminated or deactivated by the body.

    • Determines frequency of administration.

    • Short half-life (e.g., Penicillin V, t1/2=30t_{1/2} = 30 minutes) requires frequent dosing (every 4 hours for 7–10 days).

    • Long half-life (e.g., Azithromycin, t1/2=68t_{1/2} = 68 hours) requires infrequent dosing (every 24 hours for 3–5 days).

Antibacterial Drugs: Cellular Targets

Cell Wall Synthesis Inhibitors (Usually Bactericidal)
  • These drugs interfere with transpeptidation, which links peptide chains in peptidoglycan (N-acetylmuramic acid and N-acetylglucosamine).

  • Gram negative have less peptidoglycan. Negative has extra layer of outer membrane.

  • Penicillin blocks transpeptidase from building cross-link in the peptidoglycan wall, creating a weakened cell that cannot protect itself from bursting

  • This weakens the cell wall, leading to cell lysis.

  • Most effective during the exponential growth phase.

Beta-Lactam Antimicrobials

  • Characterized by a four-sided beta-lactam ring.

  • Pathogens may produce beta-lactamases, enzymes that inactivate these drugs.

  • Penicillins (suffixes end in -cillin):

    • Penicillin G: Natural, injected (acid-labile), targets Gram-positives and some gram-negatives

    • Penicillin V: Natural, oral.

    • Amoxicillin/Ampicillin: Semisynthetic, extended spectrum (Gram-negative coverage).

    • Cloxacillin/Dicloxacillin/Methicillin: Bulky R-groups provide steric hindrance against beta-lactamases; no expanded spectrum.

    • Note: MRSA (Methicillin-resistant S. aureus) and ORSA (Oxacillin-resistant S. aureus) altered their transpeptidase enzymes to avoid targeting.

  • Cephalosporins (prefixes cef- or ceph-):

    • Five generations; later generations have expanded Gram-negative activity and decreased Gram-positive activity.

    • Fifth-generation (e.g., ceftaroline) can combat MRSA/ORSA.

    • Common for patients with penicillin allergies.

  • Carbapenems (suffixes end in -penem):

    • Broad-spectrum; examples include Doripenem, Imipenem, Meropenem.

    • Rising resistance: CRE (Carbapenem-resistant Enterobacteriaceae) like Klebsiella pneumoniae and E. coli.

  • Monobactams:

    • Narrow-spectrum; example: Aztreonam.

Non-Beta-Lactam Cell Wall Inhibitors


  • Glycopeptides (e.g., Vancomycin, Teicoplanin):

    • Effective against Gram-positive organisms (MRSA).

    • Preferred for Clostridium difficile.

    • Side effects: "Red man syndrome" (itchy red flush), nephrotoxicity.

  • Bacitracin: Polypeptide; effective against Gram-positives; used in topical ointments (Neosporin).

  • Isoniazid: Interferes with mycolic acid synthesis in acid-fast bacteria (Tuberculosis treatment).

Nucleic Acid Synthesis Inhibitors (Usually Bactericidal)
  • Quinolones/Fluoroquinolones:

    • Synthetic drugs containing fluorine.

    • Target DNA replication enzymes (DNA gyrase and topoisomerases).

    • Ciprofloxacin: Effective against Mycobacterium and Pseudomonas.

    • Levofloxacin: Used for "walking pneumonia" (Mycoplasma pneumoniae).

    • Long half life - every 24 hours

  • Rifamycins (e.g., Rifampin):

    • Binds to RNA polymerase and inhibits transcription.

    • Effective against mycobacteria.

    • Can inhibit other drugs (digoxin, contraceptives, anticoagulants).

Folic Acid Synthesis Inhibitors (Antifolates; Usually Bacteriostatic)
  • Sulfa Drugs (Sulfonamides):

    • Broad-spectrum synthetic drugs.

    • Example: Sulfamethoxazole.

    • Often combined with Trimethoprim (TMP-SMX or Bactrim) for synergistic effect.

Protein Synthesis Inhibitors (Ribosome Targeting; Usually Bacteriostatic)
  • 50S Subunit Binding:

    • Macrolides: Erythromycin, Clarithromycin, Azithromycin ("Z-Pak"). Broad-spectrum.

    • Lincosamides: Clindamycin.

    • Phenicols: Chloramphenicol.

  • 30S Subunit Binding:

    • Tetracyclines (e.g., Doxycycline): Broad-spectrum. Side effects: Photosensitivity, bone/teeth effects in children under 8, risk of C. diff.

    • Aminoglycosides (suffixes -mycin or -micin): Narrow-spectrum (Gram-negative aerobic bacilli). Examples: Neomycin (topical), Gentamicin, Streptomycin. Side effects: Irreversible hearing loss and nephrotoxicity.

Plasma Membrane Disruptors (Usually Bactericidal)
  • Polypeptide Drugs (e.g., Polymyxin B, Colistin/Polymyxin E):

    • Target lipopolysaccharide (LPS) in Gram-negative outer membranes.

    • Narrow therapeutic index.

    • Used topically or as a last resort for multidrug-resistant infections (Pseudomonas aeruginosa, Acinetobacter baumannii).

Antiviral, Antifungal, and Antiparasitic Agents

  • Antiviral Challenges: Hard to target viruses without damaging host cells. Drugs primarily target active replication, not latent viruses.

    • Target categories: Attachment, penetration, uncoating, replication/assembly, release, and immune stimulation (interferons).

    • Remdesivir: First FDA-approved drug for COVID-19 (2020).

  • Antifungal Mechanisms:

    • Target ergosterol in plasma membranes (e.g., Azoles, Allylamines, Polyenes like Amphotericin B and Nystatin).

    • Target fungal cell wall synthesis (beta-glucan): Echinocandins (e.g., caspofungin acetate).

  • Antiprotozoan and Antihelminthic Drugs:

    • Difficult to develop because parasites are eukaryotes with complex life cycles.

    • Antimalarials: Chloroquine, Quinine.

    • Non-malarial: Metronidazole (Flagyl) for Toxoplasma, Giardia, Trichomonas.

    • Antihelminthic: Albendazole/Mebendazole (target microtubules/glucose uptake) and Praziquantel (paralyzes flukes/tapeworms).

Assessing Antimicrobial Sensitivity

  • Kirby-Bauer Test (Disk Diffusion):

    • Bacteria spread on Mueller-Hinton agar.

    • Antibiotic-infused disks are applied.

    • Zone of Inhibition: Clear area where growth is inhibited. Diameter is measured in millimeters (mmmm).

  • E-test: Determines the Minimum Inhibitory Concentration (MIC).

  • Interpretation:

    • Susceptible: Zone diameter falls in susceptible range.

    • Resistant: No zone or zone in resistant range.

    • Intermediate: Borderline response.

Questions & Clinical Case Scenarios

Think-pair-Share
  • Question: What structural feature of Gram-negative cell walls makes them harder for certain drugs to penetrate as compared to Gram-positive bacterial cell walls?

  • Answer Context: The outer membrane containing lipopolysaccharides (LPS) acts as an additional selective barrier in Gram-negative bacteria. Gram-positive bacteria have significantly more peptidoglycan in their cell walls than Gram-negative bacteria

Clinical Case Discussion (Chriscelle)
  • Data Provided:

    • Ampicillin: 20 mm20\,mm (Susceptible threshold ≥17 mm\ge 17\,mm) \rightarrow Susceptible.

    • Erythromycin: 15 mm15\,mm (Intermediate range 14–22 mm14\text{--}22\,mm) \rightarrow Intermediate.

    • Ceftriaxone: 25 mm25\,mm (Susceptible threshold ≥23 mm\ge 23\,mm) \rightarrow Susceptible.

    • Ciprofloxacin: 23 mm23\,mm (Susceptible threshold ≥21 mm\ge 21\,mm) \rightarrow Susceptible.

  • Questions:

    • a) What susceptibility test was done? The Kirby-Bauer (Disk Diffusion) test, as evidenced by the measurement of zone diameters in millimeters.

    • b) Based on the data, what drug(s) would you exclude? Erythromycin should be excluded as it shows only intermediate susceptibility, meaning the pathogen is not fully inhibited at standard doses.